ABBV-400 for Advanced Solid Tumors - Clinical Trial

or email

gi-oncology-cru@dm.duke.edu

What is the Purpose of this Study?

We are doing this study to find the best dose of the study drug, ABBV-400, and to see if it is a safe and effective option for treating cancer.

What is the Condition Being Studied?

Advanced Solid Tumors

Who Can Participate in the Study?

Adults ages 18+ who:

- Are diagnosed with an advanced form of cancer

- Have not seen improvement from standard therapies

For more information about who can join this study, please contact the study team at 919-668-1861.

Age Group

Adults

What is Involved?

If you choose to join this study, you will:

- Get IV infusions of the study drug every 3 weeks for up to 2 years

- Give blood and urine samples

- Have regular CT or MRI scans

Study Details

Full Title

[M21-404] A Phase 1 first in human study evaluating safety, pharmacokinetics and efficacy of ABBV-400 as monotherapy and in combination with bevacizumab in adult subjects with advanced solid tumors

Principal Investigator